Drug intelligence / Profile preview

Lu AF34134

Development stage: Unknown
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Lu AF34134 is a small molecule antagonist of the G protein-coupled receptor 6 (GPR6), developed by Lundbeck for the treatment of Parkinson's disease. GPR6 is an orphan G protein-coupled receptor that is highly and specifically expressed in the striatopallidal medium spiny neurons of the indirect pathway within the basal ganglia. In Parkinson's disease, the indirect pathway is overactive, contributing to motor deficits; by blocking GPR6, Lu AF34134 aims to reduce this overactivity and restore motor function. The drug has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics, including a food interaction crossover study in healthy young and elderly volunteers.

Targets

GPR6 (G protein-coupled receptor 6)

Beyond the preview

Go deeper on Lu AF34134.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF34134.

Explore the full profile